JDRF and global hypoglycemia experts collaborate to improve care for people with diabetes

JDRF is collaborating with an international consortium of 23 public and private organizations on a new European research study to better understand the consequences of hypoglycemia (low blood sugar) in diabetes and help alleviate the impact for those affected.

Involving 10 countries, Hypo-RESOLVE (Hypoglycemia – Redefining SOLutions for better liVEs) is a project that will span four years and aim to provide researchers and clinicians with more validated data about hypoglycemia by:

  • creating a sustainable clinical database;
  • studying the underlying mechanisms of hypoglycemia
  • identifying the predictors and consequences of hypoglycemia;
  • calculating the financial cost in European countries.

Diabetes (type 1 and 2 combined) currently affects 60 million people in Europe. Hypoglycemia, a related complication for both types of diabetes, is often a source of anxiety and fear (particularly for people on insulin therapy), since it can lead to dizziness, anxiety, rapid heartbeat, seizures and even death.

“Our mission within Hypo-RESOLVE is to provide an evidence-based classification of hypoglycemia based on secure data from 100 to 150 recently conducted clinical trials,” explains Dr. Bastiaan de Galan, coordinator of Hypo-RESOLVE and internist at the Department of Internal Medicine, Radboud University Medical Centre in the Netherlands. “With this statistical power, we will be able to make valid statements about the glucose thresholds below, which hypoglycemia constitutes a great risk for people living with diabetes.”

Hypo-RESOLVE also plans to establish a patient advisory committee to ensure that the insights, opinions and wishes of people living with diabetes are taken into account across all the multiple components of the project. As well, the study hopes to raise public awareness of both hypoglycemia and diabetes, while simultaneously creating interventions to improve treatments.

Hypo-RESOLVE is supported with funding of € 26.8 million from the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust.

Visit our JDRF Blog for more informative articles on health and type 1 diabetes news.

Lets turn type one into type none